Economic analysis of bleeding and thromboembolic sequelae after heart valve replacement (GELIA 7)

Aims To conduct an economic analysis of the coagulation-related complications bleeding and thromboembolism following heart valve replacement. Method and results: Incidences of thromboembolic and bleeding events and subtypes in the German Experience with Low Intensity Anticoagulation (GELIA) study were determined. Based on these data, stroke incidences in a hypothetical cohort of 10,000 patients were calculated over a period of 10 years. Associated lifetime costs were assigned in order to estimate the economic burden of stroke. A cost-effectiveness ratio was estimated for patient self-management of anticoagulation. In the GELIA study severe thromboembolic and bleeding complications occurred at rates of 0.45% and 2.62% per patient-year, respectively. Within the thromboembolic complications stroke was the most common (62%), whereas bleeding events were dominated by gastrointestinal bleeds (38%). For 10,000 patients, costs associated with stroke management amounted to DM26 million for thromboembolic and DM54 million for bleeding events within 10 years. In the GELIA study, patient self-management reduced the incidence of severe complications by 30%. An evaluation of selfmanagement for 5000 patients yielded a cost-effectiveness ratio of DM105,000 per life-year gained. Conclusion Major differences exist between bleeding and thromboembolic events with respect to incidence, subtype and related costs. Strokes due to bleeding exert a higher economic burden than do thromboembolic strokes. The incidence of lethal strokes may be reduced by patient self-management at an acceptable cost-effectiveness ratio. (C) 2001 The European Society of Cardiology.